GlassScriptPhysician profile
Theron R Stinar
NPI 1790883866
$6,732.10
in general payments reported to CMS, 2019-2025
38 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $931 · 2021: $1,242 · 2022: $1,097 · 2023: $1,031 · 2024: $624 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $749.30 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $687.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $513.22 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $477.02 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.01 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $364.73 | 2019-2025 | Rexulti |
| Glaxosmithkline, LLC. | $298.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $281.96 | 2019-2023 | Verquvo, Belsomra |
| Amgen INC. | $264.08 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $262.68 | 2019-2023 | Mounjaro, Trulicity |
| Allergan, INC. | $194.74 | 2019-2020 | |
| Pfizer INC. | $184.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.03 | 2019-2024 | Jardiance, Tradjenta |
| Lundbeck LLC | $172.92 | 2021-2025 | Rexulti |
| Exact Sciences Corporation | $164.77 | 2023-2025 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theron Stinar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.